ReShape Lifesciences announced that it has engaged Maxim Group LLC, to act as the Company’s exclusive financial advisor to identify potential strategic merger and acquisition partnership alternatives. The Company does not have a defined timeline for such a transaction and cannot provide any assurance whether or when any transaction will be announced or consummated.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RSLS:
- ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives
- ReShape Lifesciences: FDA approves a PMA supplement for Lap-Band 2.0 FLEX
- ReShape Lifesciences® Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band® 2.0 FLEX
- ReShape Lifesciences price target lowered to $1 from $4 at Maxim
- ReShape Lifesciences enters warrant exercise transaction for $1.2M
